Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Almorexant
Cat. No.:
0225LY-1338
Purity:
≥98%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Almorexant is a competitive dual antagonist for the orexin 1 and orexin 2 receptors, with Ki values of 1.3 nM and 0.17 nM, respectively.
Synonym:
ACT 078573; 871224-64-5; ACT-078573; (R)-2-((S)-6,7-Dimethoxy-1-(4-(trifluoromethyl)phenethyl)-3,4-dihydroisoquinolin-2(1H)-yl)-N-methyl-2-phenylacetamide; (2R)-2-((1S)-6,7-dimethoxy-1-{2-(4-(trifluoromethyl)phenyl)ethyl}-3,4-dihydroisoquinolin-2(1H)-yl)-N-methyl-2-phenylacetamide; (2R)-2-[(1S)-6,7-dimethoxy-1-[2-[4-(trifluoromethyl)phenyl]ethyl]-3,4-dihydro-1H-isoquinolin-2-yl]-N-methyl-2-phenylacetamide; (R)-2-((S)-6,7-diMethoxy-1-(4-(trifluoroMethyl)phenethyl)-3,4-dihydroisoquinolin-2(1H)-yl)-N-Methyl-; ((2r)-2-((1s)-6,7-dimethoxy-1-(2-(4-trifluoromethylphenyl)-ethyl)-3,4-dihydro-1h-isoquinolin-2-yl)-n-methyl-2-phenylacetamide)
CAS No.:
871224-64-5
Compound CID:
23727689
Formula:
C29H31F3N2O3
Formula Weight:
512.56
Specification
Targets&IC50:
OX2: 0.17 nM(ki); OX1: 1.3 nM(ki)
Relative Density:
1.205 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Almorexant can be used in sleep medicine research to evaluate the effects of competitive dual orexin receptor antagonism.
Library Information
Target:
OX receptor
Receptor:
OX1R; OX2R
Pathways:
GPCR signaling; Neuronal signaling
Plate Number:
AOCL-18
Plate Location:
b5
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
45 mg/mL; 87.79 mM
